Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.

For multiple sclerosis (MS) patients taking disease-modifying therapies (DMTs), adherence to treatment is a key component of achieving beneficial outcomes, such as delayed disease progression and the reduction and prevention of symptoms and relapses. The aim of this study was to assess the impact of a claims-based measure of MS disease severity on DMT adherence in a one-year study period. Patients were identified from Humana Medicare Advantage claims data from January 1, 2013 to December 31, 2015.